GSK PLC 2025 AR2
The report highlights GSK's strong performance in 2025, with sales increasing by 7% to £32.7 billion, driven by Specialty Medicines and Vaccines. The company achieved five major FDA approvals, including Exdensur for severe asthma and Blenrep for multiple myeloma. Under its responsible business agenda, GSK met or exceeded 92% of its performance metrics, delivering 99 million vaccine doses to Gavi and achieving a 14% reduction in operational carbon emissions (Scope 1 and 2) since 2024. Additionally, the company advanced its net-zero transition, with 100% of its own sites and key suppliers meeting active pharmaceutical ingredient wastewater discharge limits.
Company: GSK PLC
Sector: Health Care
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 107
GSK PLC
Annual Report
The report highlights GSK's strong performance in 2025, with sales increasing by 7% to £32.7 billion, driven by Specialty Medicines and Vaccines. The company achieved five major FDA approvals, including Exdensur for severe asthma and Blenrep for multiple myeloma. Under its responsible business agenda, GSK met or exceeded 92% of its performance metrics, delivering 99 million vaccine doses to Gavi and achieving a 14% reduction in operational carbon emissions (Scope 1 and 2) since 2024. Additionally, the company advanced its net-zero transition, with 100% of its own sites and key suppliers meeting active pharmaceutical ingredient wastewater discharge limits.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees